GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » Total Assets

ACADIA Pharmaceuticals (FRA:DR6) Total Assets : €786.7 Mil (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Total Assets?

ACADIA Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was €786.7 Mil.

Warning Sign:

If a company builds assets at 32.8% a year, faster than its revenue growth rate of 17.5% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, ACADIA Pharmaceuticals's average Total Assets Growth Rate was 52.40% per year. During the past 3 years, the average Total Assets Growth Rate was 27.20% per year. During the past 5 years, the average Total Assets Growth Rate was 32.80% per year. During the past 10 years, the average Total Assets Growth Rate was 61.20% per year.

During the past 13 years, ACADIA Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 144.00%. The lowest was -49.20%. And the median was 27.20%.

Total Assets is connected with ROA %. ACADIA Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 was 8.27%. Total Assets is also linked to Revenue through Asset Turnover. ACADIA Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 was 0.26.


ACADIA Pharmaceuticals Total Assets Historical Data

The historical data trend for ACADIA Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Total Assets Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 704.87 643.31 619.61 554.90 686.79

ACADIA Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 612.06 593.28 592.69 686.79 786.70

ACADIA Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

ACADIA Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=395.919+290.873
=686.8

ACADIA Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=426.92+359.774
=786.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ACADIA Pharmaceuticals  (FRA:DR6) Total Assets Explanation

Total Assets is connected with ROA %.

ACADIA Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=60.924/( (686.793+786.695)/ 2 )
=60.924/736.744
=8.27 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

ACADIA Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=189.365/( (686.793+786.695)/ 2 )
=189.365/736.744
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

ACADIA Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


ACADIA Pharmaceuticals (FRA:DR6) Business Description

Traded in Other Exchanges
Address
12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

ACADIA Pharmaceuticals (FRA:DR6) Headlines

No Headlines